

Accelerated Discovery and Development of New Medicines

A University of Strathclyde - University of Nottingham - GSK Partnership

The Universities of Nottingham and Strathclyde are collaborating on an EPSRC-funded partnership with GlaxoSmithKline (GSK) on the Accelerated Discovery & Development of New Medicines. Driven by Strathclyde and Nottingham's world-leading research expertise, and informed by GSK's Innovation, Performance and Trust agenda, this 5-year programme will build on the existing collaborations between the three partners, to deliver a new suite of methods and approaches that tackle the major challenges in the discovery, development, and manufacture of medicines. Our vision is to enable the production of novel, transformative medicines at lower costs, with reduced waste production and shorter manufacturing times.

One of the four research themes for the programme focuses on developing and applying AI and machine learning to the efficient identification of next generation medicines and we are currently seeking applications for the following roles to work in this area:

Research Associate/Fellow in Computational Chemistry (University of Nottingham)

In this role, in the research group of Professor Jonathan Hirst, you will focus on improving the accuracy of computational predictions of protein-ligand binding affinity utilising new advances in machine learning and apply these techniques within specific medicinal chemistry programmes to design drug-like molecules. For further details of this role please follow this link [SCI027521X2 Research Associate/Fellow in Computational Chemistry \(Fixed-term\) - Jobs at the University of Nottingham](#). Closing date for applications: Thursday 1st July 2021

Research Associate/Fellow in Synthetic & Medicinal Chemistry (University of Nottingham)

This role, based in the research group of Professor Mike Stocks, will involve the development of a medicinal chemistry research project founded upon excellence in synthetic (medicinal) chemistry aimed at supporting an artificial intelligence (AI) enabled medicinal chemistry program. The successful candidate will work in collaboration with an AI computational chemist to explore the proof-of-concept chemical synthesis of new lead- and drug-like chemical scaffolds, enabling the synthesis of the scaffold and the expansion of the scaffolds into small "drug-like" libraries. An essential aspect of the research will be the validation of synthetic chemistry reactions to expedite the generation of compound libraries, through short-term secondment access to GSK's high throughput chemistry expertise. For further details of this role please follow this link [SCI202121 Research Associate/Fellow \(fixed term\) - Jobs at the University of Nottingham](#) Closing date for applications: Thursday 22nd July 2021

It is expected that the successful candidates will work closely with researchers at The University of Strathclyde and GSK with an opportunity to undertake secondments to one or both of our partner institutions.

If you would like to apply your knowledge to accelerate discovery and development of new medicines for patients, whilst also receiving training from three world-class academic and pharmaceutical institutions in an integrated programme from discovery to manufacturing, then apply to this programme.

GSK, the University of Nottingham, and the University of Strathclyde are proud to promote an open culture, encouraging people to be themselves and giving ideas a chance to flourish. We are equal opportunities

employers and welcome applications regardless of gender, age, ethnicity, disability, sexual orientation, country of origin, or country of application.



University of Nottingham
UK | CHINA | MALAYSIA

Together we can make life better.



EPSRC

Engineering and Physical Sciences
Research Council